NOVARTIS logo.jpg
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
July 19, 2022 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33%...
NOVARTIS logo.jpg
Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022
July 19, 2022 01:00 ET | Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im zweiten Quartal um +5% kWk1 (–1% USD) Innovative Medicines (IM) steigerte den Umsatz um +5% kWk (–1% USD); starke Performance der wichtigsten...
NOVARTIS logo.jpg
Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe
July 19, 2022 01:00 ET | Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T2 en hausse de +5% tcc1 (-1% USD) Innovative Medicines (IM): hausse du chiffre d’affaires de +5% (tcc, -1% USD), avec...
NOVARTIS logo.jpg
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
June 30, 2022 04:00 ET | Novartis Pharma AG
First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal...
NOVARTIS logo.jpg
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
June 22, 2022 19:12 ET | Novartis Pharma AG
Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with...
NOVARTIS logo.jpg
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study
June 06, 2022 08:00 ET | Novartis Pharma AG
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in...
NOVARTIS logo.jpg
Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
May 20, 2022 08:34 ET | Novartis Pharma AG
Positive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these...
NOVARTIS logo.jpg
Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
May 12, 2022 10:28 ET | Novartis Pharma AG
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new...
NOVARTIS logo.jpg
New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
May 04, 2022 03:00 ET | Novartis Pharma AG
With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for...
NOVARTIS logo.jpg
Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
April 27, 2022 06:00 ET | Novartis Pharma AG
RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with...